Skip to main content
Top
Published in: Supportive Care in Cancer 10/2020

Open Access 01-10-2020 | Radiotherapy | Original Article

A proposed tailored investigational algorithm for women treated for gynaecological cancer with long-term gastrointestinal consequences

Authors: Ann Muls, Alexandra Taylor, Susan Lalondrelle, Mohammed Kabir, Christine Norton, Ailsa Hart, H. Jervoise Andreyev

Published in: Supportive Care in Cancer | Issue 10/2020

Login to get access

Abstract

Background and aim

Long-term changes in gastrointestinal function impacting quality of life after treatment for cancer are common. Peer reviewed guidance to investigate and manage GI dysfunction following cancer treatment has been published. This study reviewed gastrointestinal symptoms of women previously treated for gynaecological cancer and considered whether suggested algorithms could be amended to optimise management for this cohort.

Methods

Demographic and clinical data recorded for patients attending a specialist consequences of cancer treatment gastroenterology service prospectively are reported using median and range. The Wilcoxon signed rank test analysed changes in symptoms between initial assessment to discharge from the service.

Results

Between April 2013 and March 2016, 220 women, with a median age of 57 years (range 24–83 years), treated for gynaecological cancer (cervical (50%)), endometrial (28%), ovarian (15%), vaginal or vulval (7%) attended. Twelve gastrointestinal symptoms were statistically significantly reduced by time of discharge from the specialist gastroenterology clinic including bowel frequency ≥ 4/day (88%), type 6 or 7 stool consistency (36%), urgency (31%) and incontinence (21%). General quality of life improved from a median score of 4 at first assessment to a median of 6 at discharge (p < 0.001). A median of four (range, 1–9) diagnoses were made.

Conclusion

Women with gastrointestinal symptoms after cancer treatment benefit from a systematic management approach. After excluding disease recurrence, a proposed investigational algorithm and the oncology team includes FBC, U&Es, LFTs, thyroid function test, vitamin B12, vitamin D, a hydrogen methane breath test and a SeHCAT scan. If rectal bleeding is present, iron studies, flexible sigmoidoscopy or colonoscopy should be performed. Patients with normal investigations or symptoms not responding to treatment require gastroenterology input.
Literature
4.
go back to reference Andreyev HJN, Benton BE, Lalji A et al (2013) Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet 382:2084–2092CrossRefPubMed Andreyev HJN, Benton BE, Lalji A et al (2013) Algorithm-based management of patients with gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): a randomised controlled trial. Lancet 382:2084–2092CrossRefPubMed
5.
go back to reference Muls A, Lalji A, Marshall C, Butler L, Shaw C, Vyoral S, Mohammed K, Andreyev HJ (2016) The holistic management of consequences of cancer treatment by a gastrointestinal and nutrition team: a financially viable approach to an enormous problem? Clin Med 16(3):240–246CrossRef Muls A, Lalji A, Marshall C, Butler L, Shaw C, Vyoral S, Mohammed K, Andreyev HJ (2016) The holistic management of consequences of cancer treatment by a gastrointestinal and nutrition team: a financially viable approach to an enormous problem? Clin Med 16(3):240–246CrossRef
6.
go back to reference Andreyev HJN, Muls AC, Norton C, Ralph C, Watson L, Shaw C, Lindsay JO (2015) Guidance: the practical management of the gastrointestinal symptoms of pelvic radiation disease. Frontline Gastroenterol 6(1):53–72CrossRefPubMed Andreyev HJN, Muls AC, Norton C, Ralph C, Watson L, Shaw C, Lindsay JO (2015) Guidance: the practical management of the gastrointestinal symptoms of pelvic radiation disease. Frontline Gastroenterol 6(1):53–72CrossRefPubMed
12.
go back to reference Revicki DA, Wood M, Wiklund I, Crawley J (1998) Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 7:75–83CrossRefPubMed Revicki DA, Wood M, Wiklund I, Crawley J (1998) Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 7:75–83CrossRefPubMed
13.
go back to reference Van den Heuvel-Janssen HA, Borghouts JA, Muris JW et al (2006) Chronic non-specific abdominal complaints in general practice: a prospective study on management, patient health status and course of complaints. BMC FamPract 7:1–8 Van den Heuvel-Janssen HA, Borghouts JA, Muris JW et al (2006) Chronic non-specific abdominal complaints in general practice: a prospective study on management, patient health status and course of complaints. BMC FamPract 7:1–8
14.
go back to reference Iwarzon M, Gardulf A, Lindberg G (2009) Functional status, health- related quality of life and symptom severity in patients with chronic intestinal pseudo-obstruction and enteric dysmotility. Scand J Gastroenterol 44:700–707CrossRefPubMed Iwarzon M, Gardulf A, Lindberg G (2009) Functional status, health- related quality of life and symptom severity in patients with chronic intestinal pseudo-obstruction and enteric dysmotility. Scand J Gastroenterol 44:700–707CrossRefPubMed
16.
go back to reference Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32:920–924CrossRefPubMed Lewis SJ, Heaton KW (1997) Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 32:920–924CrossRefPubMed
19.
go back to reference London Cancer Alliance. E-HNA data analysis: What are people’s most commonly reported concerns? 1st April 2014–31 March 2015. Presentation data 2015 London Cancer Alliance. E-HNA data analysis: What are people’s most commonly reported concerns? 1st April 2014–31 March 2015. Presentation data 2015
20.
go back to reference Hauer-Jensen M, Denham JW, Andreyev HJ (2014) Radiation enteropathy--pathogenesis, treatment and prevention. Nat Rev Gastroenterol Hepatol 11(8):470–479CrossRefPubMedPubMedCentral Hauer-Jensen M, Denham JW, Andreyev HJ (2014) Radiation enteropathy--pathogenesis, treatment and prevention. Nat Rev Gastroenterol Hepatol 11(8):470–479CrossRefPubMedPubMedCentral
21.
go back to reference Farnell D, Staffurth J, Sivell S et al (2019) The ALERT-B questionnaire provides a clinically validated questionnaire for the detection of gastroenterological late effects after radiotherapy for prostate cancer. Submitted for publication to Radiotherapy and Oncology Farnell D, Staffurth J, Sivell S et al (2019) The ALERT-B questionnaire provides a clinically validated questionnaire for the detection of gastroenterological late effects after radiotherapy for prostate cancer. Submitted for publication to Radiotherapy and Oncology
28.
go back to reference Snijders-Keilholz A, Griggoen G, Davelaar J, Trimbos J, Leer J (1993) Vitamin B12 malabsorption after irradiation for gynaecoligical tumours. Anticancer Res 13(5):1877–1881PubMed Snijders-Keilholz A, Griggoen G, Davelaar J, Trimbos J, Leer J (1993) Vitamin B12 malabsorption after irradiation for gynaecoligical tumours. Anticancer Res 13(5):1877–1881PubMed
29.
go back to reference Grace E, Shaw C, Whelan K, Andreyev J (2013) Review article: small intestinal bacterial overgrowth--prevalence clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 38(7):674–688CrossRefPubMed Grace E, Shaw C, Whelan K, Andreyev J (2013) Review article: small intestinal bacterial overgrowth--prevalence clinical features, current and developing diagnostic tests, and treatment. Aliment Pharmacol Ther 38(7):674–688CrossRefPubMed
30.
go back to reference National Institute of Clinical Excellence (2015) Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use: NICE guideline. NICE 2015; 25pp. Accessed August 2019 via www.nice.org.uk/guidance/ng15 National Institute of Clinical Excellence (2015) Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use: NICE guideline. NICE 2015; 25pp. Accessed August 2019 via www.​nice.​org.​uk/​guidance/​ng15
31.
go back to reference Wedlake L, A’hern R, Russel D et al (2009) Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 30:707–717CrossRefPubMed Wedlake L, A’hern R, Russel D et al (2009) Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 30:707–717CrossRefPubMed
36.
go back to reference Taylor A, Fernandes A, Kumar P et al (2016) Acute and chronic toxicity of pelvic radiotherapy. In: Textbook of gynaecological oncology, 3rd edn. The European Soiaty of Gynaecological Oncology. Chapter 138. 12pp Taylor A, Fernandes A, Kumar P et al (2016) Acute and chronic toxicity of pelvic radiotherapy. In: Textbook of gynaecological oncology, 3rd edn. The European Soiaty of Gynaecological Oncology. Chapter 138. 12pp
Metadata
Title
A proposed tailored investigational algorithm for women treated for gynaecological cancer with long-term gastrointestinal consequences
Authors
Ann Muls
Alexandra Taylor
Susan Lalondrelle
Mohammed Kabir
Christine Norton
Ailsa Hart
H. Jervoise Andreyev
Publication date
01-10-2020
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 10/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05309-z

Other articles of this Issue 10/2020

Supportive Care in Cancer 10/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine